Morgan Stanley Rigel Pharmaceuticals Inc Call Options Transaction History
Morgan Stanley
- $1.23 Trillion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding RIGL
# of Institutions
122Shares Held
110MCall Options Held
556KPut Options Held
33.9K-
Armistice Capital, LLC New York, NY15.4MShares$119 Million0.31% of portfolio
-
Black Rock Inc. New York, NY14.8MShares$114 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.37MShares$72.4 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT9.24MShares$71.4 Million1.12% of portfolio
-
Acadian Asset Management LLC Boston, MA5.47MShares$42.2 Million0.03% of portfolio
About RIGEL PHARMACEUTICALS INC
- Ticker RIGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 172,836,000
- Market Cap $1.34B
- Description
- Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...